207 related articles for article (PubMed ID: 37762133)
1. Inhibition of HSP90 in Driver Oncogene-Defined Lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy.
Marrugal Á; Ferrer I; Quintanal-Villalonga Á; Ojeda L; Pastor MD; García-Luján R; Carnero A; Paz-Ares L; Molina-Pinelo S
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762133
[TBL] [Abstract][Full Text] [Related]
2. Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry.
Marrugal Á; Ferrer I; Pastor MD; Ojeda L; Quintanal-Villalonga Á; Carnero A; Molina-Pinelo S; Paz-Ares L
Cells; 2019 Jul; 8(8):. PubMed ID: 31370342
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene.
Chen Z; Sasaki T; Tan X; Carretero J; Shimamura T; Li D; Xu C; Wang Y; Adelmant GO; Capelletti M; Lee HJ; Rodig SJ; Borgman C; Park SI; Kim HR; Padera R; Marto JA; Gray NS; Kung AL; Shapiro GI; Jänne PA; Wong KK
Cancer Res; 2010 Dec; 70(23):9827-36. PubMed ID: 20952506
[TBL] [Abstract][Full Text] [Related]
4. Identification of Predictive Biomarkers of Response to HSP90 Inhibitors in Lung Adenocarcinoma.
Marrugal Á; Ferrer I; Gómez-Sánchez D; Quintanal-Villalonga Á; Pastor MD; Ojeda L; Paz-Ares L; Molina-Pinelo S
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33802597
[TBL] [Abstract][Full Text] [Related]
5. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.
Heuckmann JM; Balke-Want H; Malchers F; Peifer M; Sos ML; Koker M; Meder L; Lovly CM; Heukamp LC; Pao W; Küppers R; Thomas RK
Clin Cancer Res; 2012 Sep; 18(17):4682-90. PubMed ID: 22912387
[TBL] [Abstract][Full Text] [Related]
6. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
7. Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.
Xia N; An J; Jiang QQ; Li M; Tan J; Hu CP
Exp Lung Res; 2013 Oct; 39(8):328-35. PubMed ID: 23919423
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
[TBL] [Abstract][Full Text] [Related]
9. Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.
Zhang Y; Sun Y; Pan Y; Li C; Shen L; Li Y; Luo X; Ye T; Wang R; Hu H; Li H; Wang L; Pao W; Chen H
Clin Cancer Res; 2012 Apr; 18(7):1947-53. PubMed ID: 22317764
[TBL] [Abstract][Full Text] [Related]
10. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance.
Shimamura T; Li D; Ji H; Haringsma HJ; Liniker E; Borgman CL; Lowell AM; Minami Y; McNamara K; Perera SA; Zaghlul S; Thomas RK; Greulich H; Kobayashi S; Chirieac LR; Padera RF; Kubo S; Takahashi M; Tenen DG; Meyerson M; Wong KK; Shapiro GI
Cancer Res; 2008 Jul; 68(14):5827-38. PubMed ID: 18632637
[TBL] [Abstract][Full Text] [Related]
11. HSP90 inhibitors in lung cancer: promise still unfulfilled.
Chatterjee S; Bhattacharya S; Socinski MA; Burns TF
Clin Adv Hematol Oncol; 2016 May; 14(5):346-56. PubMed ID: 27379696
[TBL] [Abstract][Full Text] [Related]
12. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells.
Taniguchi H; Yamada T; Wang R; Tanimura K; Adachi Y; Nishiyama A; Tanimoto A; Takeuchi S; Araujo LH; Boroni M; Yoshimura A; Shiotsu S; Matsumoto I; Watanabe S; Kikuchi T; Miura S; Tanaka H; Kitazaki T; Yamaguchi H; Mukae H; Uchino J; Uehara H; Takayama K; Yano S
Nat Commun; 2019 Jan; 10(1):259. PubMed ID: 30651547
[TBL] [Abstract][Full Text] [Related]
13. Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells.
Tanimoto A; Yamada T; Nanjo S; Takeuchi S; Ebi H; Kita K; Matsumoto K; Yano S
Oncotarget; 2014 Jul; 5(13):4920-8. PubMed ID: 24952482
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of heat shock protein 90 destabilizes receptor tyrosine kinase ROR1 in lung adenocarcinoma.
Khaledian B; Taguchi A; Shin-Ya K; Kondo-Ida L; Kagaya N; Suzuki M; Kajino T; Yamaguchi T; Shimada Y; Takahashi T
Cancer Sci; 2021 Mar; 112(3):1225-1234. PubMed ID: 33370472
[TBL] [Abstract][Full Text] [Related]
15. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.
Yamaoka T; Ohmori T; Ohba M; Arata S; Kishino Y; Murata Y; Kusumoto S; Ishida H; Shirai T; Hirose T; Ohnishi T; Sasaki Y
Mol Cancer Ther; 2016 Dec; 15(12):3040-3054. PubMed ID: 27612490
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.
Kim H; Yang JM; Jin Y; Jheon S; Kim K; Lee CT; Chung JH; Paik JH
Oncotarget; 2017 Jan; 8(5):8484-8498. PubMed ID: 28035073
[TBL] [Abstract][Full Text] [Related]
17. Luteolin is effective in the non-small cell lung cancer model with L858R/T790M EGF receptor mutation and erlotinib resistance.
Hong Z; Cao X; Li N; Zhang Y; Lan L; Zhou Y; Pan X; Shen L; Yin Z; Luo L
Br J Pharmacol; 2014 Jun; 171(11):2842-53. PubMed ID: 24471765
[TBL] [Abstract][Full Text] [Related]
18. EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas.
Jorge SE; Lucena-Araujo AR; Yasuda H; Piotrowska Z; Oxnard GR; Rangachari D; Huberman MS; Sequist LV; Kobayashi SS; Costa DB
Clin Cancer Res; 2018 Dec; 24(24):6548-6555. PubMed ID: 30154228
[TBL] [Abstract][Full Text] [Related]
19. The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.
Qu Y; Che N; Zhao D; Zhang C; Su D; Zhou L; Zhang L; Wang C; Zhang H; Wei L
Tumour Biol; 2015 Aug; 36(8):6417-24. PubMed ID: 25813151
[TBL] [Abstract][Full Text] [Related]
20. Docosahexaenoic Acid-mediated Inhibition of Heat Shock Protein 90-p23 Chaperone Complex and Downstream Client Proteins in Lung and Breast Cancer.
Mouradian M; Ma IV; Vicente ED; Kikawa KD; Pardini RS
Nutr Cancer; 2017 Jan; 69(1):92-104. PubMed ID: 27880046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
